We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Roquefort Therapeutics Plc | LSE:ROQ | London | Ordinary Share | GB00BMDQ2T15 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.20 | 5.56% | 3.80 | 3.60 | 4.00 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 3.80 | 3.70 | 3.70 | 335,421 | 15:32:42 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Cmp Integrated Sys Design | 200k | -1.75M | -0.0135 | -2.81 | 4.65M |
| Date | Time | Source | Headline |
|---|---|---|---|
| 02/1/2025 | 14:08 | ALNC |  Roquefort Therapeutics proposes USD10 million subsidiary sale |
| 02/1/2025 | 07:00 | UK RNS | Roquefort Therapeutics PLC Proposed Sale of Midkine Portfolio |
| 04/12/2024 | 16:00 | UK RNS | Roquefort Therapeutics PLC Director Share Distribution |
| 07/11/2024 | 07:00 | UK RNS | Roquefort Therapeutics PLC Conversion of Convertible Loan Notes |
| 06/11/2024 | 07:00 | UK RNS | Roquefort Therapeutics PLC STAT-6 siRNA Presentation |
| 27/9/2024 | 12:56 | ALNC | EARNINGS: Kendrick Resources loss narrows; Emmerson CFO to depart |
| 27/9/2024 | 06:00 | UK RNS | Roquefort Therapeutics PLC Interim Results to 30 June 2024 |
| 23/9/2024 | 16:51 | ALNC | Roquefort Therapeutics says MK cell therapy patent approved in Japan |
| 23/9/2024 | 06:00 | UK RNS | Roquefort Therapeutics PLC Grant of Japan MK Cell Patent |
| 19/9/2024 | 06:00 | UK RNS | Roquefort Therapeutics PLC STAT-6 siRNA Demonstrates Efficacy in Immunology |
1 Year Roquefort Therapeutics Chart |
Intraday Roquefort Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
